-
- 抗原
- FLJ11730
-
适用
- 人
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- 非结合性
- 应用范围
- Immunohistochemistry (IHC), Western Blotting (WB), ELISA
- 纯化方法
- Antibody is purified by peptide affinity chromatography method.
- 免疫原
- Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human FLJ11730.
-
anti-FLJ11730 (N-Term) antibody
适用: 人 IHC, WB 宿主: 兔 Polyclonal unconjugated
anti-FLJ11730 (N-Term) antibody适用: 人, Cow, 小鼠, 大鼠, 斑马鱼 IHC, WB 宿主: 兔 Polyclonal unconjugated
-
- 应用备注
- FLJ11730 antibody can be used for detection of FLJ11730 by ELISA at 1:312500. FLJ11730 antibody can be used for detection of FLJ11730 by western blot at 0.5 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50,000 - 100,000.
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 溶解方式
- Add 50 ?L of distilled water. Final antibody concentration is 1 mg/mL.
- 浓度
- 1 mg/mL
- 缓冲液
- Antibody is lyophilized in PBS buffer with 2 % sucrose.
- 注意事项
- As with any antibody avoid repeat freeze-thaw cycles.
- 储存条件
- 4 °C/-20 °C
- 储存方法
- For short periods of storage (days) store at 4 °C. For longer periods of storage, store FLJ11730 antibody at -20 °C.
-
- 抗原
- FLJ11730
- 背景
- The screening of cDNA expression libraries from human tumors with serum antibody (SEREX) has proven to be a powerful method for identifying the repertoire of tumor antigens recognized by the immune system of cancer patients, referred to as the cancer immunome. In this regard, cancer/testis (CT) antigens are of particular interest because of their immunogenicity and restricted expression patterns. Synoivial sarcomas are striking with regard to CT antigen expression, however, highly expressed in sarcoma, CT antigens do not induce frequent humoral immune responses in sarcoma patients. Sera from two patients were used to immunoscreen cDNA libraries from two synovial sarcoma cell lines and normal testis, resulting in the identification of 113 distinct antigens. Sarcoma antigen NY-SAR-91 is one of them.
- 分子量
- 23 kDa
- 基因ID
- 64769
- NCBI登录号
- NP_073593
- UniProt
- Q86WE3
-
You are here:
